Wal-Mart adds 11 generic drugs to discounted prescription drug program

Wal-Mart Stores on Thursday announced that it will begin selling eight additional generic drugs for $4 per 30-day prescription and several family-planning drugs for $9, USA Today reports (Appleby, USA Today, 9/28).

The added medications include treatments for glaucoma, attention deficit disorder, attention deficit hyperactivity disorder, fungal infections and acne (Albright, St. Petersburg Times, 9/28). In addition, Wal-Mart will offer generic versions of the birth control drugs Ortho Cyclen and Ortho Tri-Cyclen and a fertility drug for $9 per 30-day supply.

The discount drug program, which started in September 2006, now will cover 361 prescriptions representing different formulations of 157 generic drugs (Saul, New York Times, 9/28). The new additions add about 24 prescriptions to the program (Bernstein, Long Island Newsday, 9/28).

According to Wal-Mart Chief Operating Officer Bill Simon, the program has saved customers and the U.S. health care system $610 million (New York Times, 9/28). Other retail chains, including Kmart, Publix and Target, have advertised similar programs (St. Petersburg Times, 9/28). Target officials on Thursday said the company would match Wal-Mart's discounts in all prescriptions categories, the Newark Star-Ledger reports (May, Newark Star-Ledger, 9/28). The company said that the $4 program accounts for about 40% of prescription drug sales at its pharmacies and is profitable (St. Petersburg Times, 9/28).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Review of natural products with promising anti-SARS-CoV-2 potential